Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …

For advanced metastatic non-small-lung cancer, the landscape of actionable driver
alterations is rapidly growing, with nine targetable oncogenes and seven approvals within …

Following respiratory viral infection, regeneration of the epithelial barrier is required to
preserve lung function and prevent secondary infections. Lung regulatory T (Treg) cells are …

Background Anti-depressants have been reported to own anti-tumor potential types of
cancers; however, the role of imipramine in non-small cell lung cancer (NSCLC) has not …

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) represented by
gefitinib and erlotinib are widely used in treating non-small cell lung cancer (NSCLC) …

Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) …

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic driver
in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase …

Medication-induced pulmonary injury (MIPI) is a complex medical condition that has become
increasingly common yet remains stubbornly difficult to diagnose. Diagnosis can be aided …

Codonopsis lanceolata is a perennial smelly herbaceous plant and widely employed for the
treatment of various lung cancer and inflammation. However, the anticancer substances in …

Diarrhea is an important adverse effect of epidermal growth factor receptor-tyrosine kinase
inhibitors, especially afatinib. Novel antidiarrheal agents are needed to reduce epidermal …